This open access journal publishes peer reviewed articles on clinical studies, real world evidence data, reviews, point of views, case series, and single clinical cases. The journal aim and scope encompasses clinical medicine, pharmacy, healthcare technology and other healthcare related disciplines with a focus on innovation in healthcare and policy. Articles may be in English, French, Italian and Spanish
Health technology assessment (HTA) is a discipline in which global policies and guidelines are applied at regional level. Global and Regional Health Technology Assessment (GRHTA) is an international, indexed, peer-reviewed, open access, online only journal, which aims to promote health technology assessment and economic evaluation globally and/or regionally, supporting the decision-making process among alternative therapeutical approaches and technologies with different clinical and economic outcomes.
The journal focuses on the role of scientific and technological advancement in reaching higher healthcare standards and on the intrinsic limitations within each region in allocating resources in healthcare. These topics are of great relevance to the local academic communities and policymakers for their impact on healthcare governance in different countries.
The journal publishes new articles continuously, as soon as they are ready for publication to guarantee rapid and efficient publication times and a content distribution to its indexing databases and then collects them in a yearly issue.
Giornale di Clinica Nefrologica e Dialisi (GCND), formerly Giornale di Tecniche Nefrologiche e Dialitiche, is an online only, peer-reviewed, continuous publication journal addressing topics of interest for nephrologists, nephrology specialists, dialysis and transplant nephrology nurses, dialysis technicians, kidney dietitians and patients.
About the Journal
Drug Target Insights (DTI) is an international, indexed, peer-reviewed, open access, online only journal, published once a year. It covers current developments in all areas of the field of clinical therapeutics, focusing on molecular drug targets which include disease-specific proteins, receptors, enzymes, and genes. The journal seeks to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life and welcomes unsolicited article proposals. All articles are listed on PubMed and are freely available via PubMed Central.
DTI publishes new articles as soon as they are ready for publication (online first, as customary now for scientific journals) and then collected in an issue, to guarantee rapid publication times and a timely content availability for its indexing databases. DTI features two monothematic sections (Antimicrobial resistance (AMR) and Phytotherapeutics and natural products), each guided by an dedicated and experienced editor.
The antimicrobial resistance section considering contributions dedicated tI the antimicrobial resistant infections caused by viruses, bacteria, fungi, protozoa, and helminths, mechanisms of antimicrobial resistance, identification and validation of novel molecular and cellular targets among pathogens and other relevant topics.
The phytotherapeutics and natural products section focuses on the health-promoting effects of natural products and phytotherapeutics as promising agents in the prevention and treatment of communicable and non-communicable diseases. Both preclinical (in vitro/in vivo) and clinical (in humans) studies are considered.
Journal of Circulating Biomarkers is an international, peer-reviewed, open access scientific journal focusing on all aspects of the rapidly growing field of circulating blood-based biomarkers and diagnostics using circulating protein and lipid markers, circulating tumor cells (CTC), circulating cell-free DNA (cfDNA) and extracellular vesicles, including exosomes, microvesicles, microparticles, ectosomes and apoptotic bodies.
For the benefits of our readers, we host on this platform Cancer Breaking News, an open access peer reviewed journal promoting the debate and interaction between young physicians, leaders and qualified experts in oncology, published from 2013 to 2017.